Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsPolitics

Panacea Biotec Q1 loss narrows to Rs 28.27 cr

The company had posted a net loss of Rs 35.26 crore from continuing and discontinued operations for the corresponding period of the previous fiscal, Panacea Biotec said in a regulatory filing.

August 16, 2019 / 03:43 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Panacea Biotec has reported narrowing of its consolidated net loss to Rs 28.27 crore for the quarter ended June 30, 2019.

The company had posted a net loss of Rs 35.26 crore from continuing and discontinued operations for the corresponding period of the previous fiscal, Panacea Biotec said in a regulatory filing.

Revenue from operations stood at Rs 125.78 crore for the quarter under review as against Rs 99.28 crore for the same period a year ago.

"The company's remediation measures have now started paying off. The company has registered impressive financial performance during the quarter ended June 30, 2019 with 28 per cent topline growth and earning positive earnings before interest, taxes, depreciation and amortization (EBITDA) of Rs 26.9 crore," Panacea Biotec MD Rajesh Jain said.

This performance is expected to continue in future periods as well, he added.

During the quarter, the company received United States Food and Drug Administration (USFDA) approval for Oncology Parenteral Formulations facility at Baddi in Himachal Pradesh for the manufacture and supply of Azacitidine injection 100 mg/vial in the US market and has launched this product in US, Panacea Biotec said.

Shares of Panacea Biotec were trading at Rs 144 per scrip on BSE, down 2.64 per cent from the previous close.

PTI
first published: Aug 16, 2019 03:36 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347